Health authorities have identified highly concentrated tramadol drop solutions as a major source of medication errors in children.
The need to count drops — up to 40 per administration depending on body weight — has led to serious overdoses and hospitalizations.
In this context, several markets are moving toward presentations enabling volumetric dosing rather than drop counting.
For pharmaceutical companies, this evolution creates a dual opportunity:
- secure the use of a sensitive active substance (opioid)
- modernize a mature molecule through a pediatric-adapted presentation
